BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Protectimmun Gets Positive Scientific Advice Response From European Medicines Agency For Innovative Allergy Prophylaxis


12/3/2013 8:38:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gelsenkirchen, Germany, December 3, 2013 / B3C newswire / - Protectimmun GmbH has successfully discussed the overall clinical development plan for its innovative allergy prophylaxis against hay fever and allergic asthma in a Scientific Advice Meeting with the European Medicines Agency (EMA). The Agency agreed to the biological rationale of the allergy prevention concept and endorses the proposed key elements of the clinical safety and efficacy studies including study population, duration, and endpoints.

"We are very pleased to get this favourable opinion from EMA’s medical experts”, says Marion Kauth, CEO and co-founder of Protectimmun. "It is the reward for our efforts to elaborate the complete development plan for this first-in-class innovation at the earliest and to carefully consider the special issues for a preventive approach in children.”

Nose drops for the prevention of hay fever and asthma

Protectimmun is a pharmaceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its lead development is a first-in-class medicinal product that may offer long-lasting protection against the development of hay fever and allergic asthma in infants. The product contains probiotic bacteria from a specific farm environment and will be applied as nose drops. Application via the nasal mucosa mimics the natural exposure of farm children by intensive barn contact in early life that has been shown to be allergy-protective in large epidemiological studies. More than 5 million infants would be eligible for this preventive treatment in Europe and the USA each year.

Professor Albrecht Bufe, paediatrician and co-founder of the company, comments: „Allergic airway diseases have been steadily increasing over the last 60 years and treatment options are so far quite limited. Therefore, a safe and effective primary prophylaxis is a significant unmet medical need. Nowadays, every child in Europe and North America has a 20% risk of developing allergic airway disease and this risk increases up to 70% for children of allergic parents.”

Broad proof-of-concept has been established in relevant animal models and pre-clinical toxicity and safety testing has successfully been completed so that the project is prepared to enter the clinical Phase. “Having met this milestone we are looking forward to discuss the project with investors and established companies for partnering to expedite the clinical development”, states Marion Kauth.

Contact Information

Protectimmun GmbH

Dr. Marion Kauth

Chief Executive Officer

Tel.: +49 (0)209 38971363

e-mail: info@protectimmun.de

http://www.protectimmun.de

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES